prevention of macrovascular complications of diabetes · 1. to recognize macrovascular...
TRANSCRIPT
![Page 1: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/1.jpg)
Prevention of
MACROvascular
Complications of
Diabetes Matt Bouchonville, MD, CDE
Endocrinology Division
University of New Mexico School of Medicine
July 12, 2018
![Page 2: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/2.jpg)
None
Conflicts of Interest
![Page 3: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/3.jpg)
1. To recognize macrovascular complications as the leading cause of death in people with diabetes
2. To be familiar with risk factors for macrovascular complications of diabetes
3. To understand the impact of multifactorial risk reduction on outcomes in patients with diabetes
Objectives
![Page 4: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/4.jpg)
Microvascular =
small vessel disease
Macrovascular =
large vessel disease
![Page 5: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/5.jpg)
Overview of Diabetic Complications
Leading cause
of death in
people with
diabetes
![Page 6: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/6.jpg)
Diabetes Care 2018;41(S1).
![Page 7: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/7.jpg)
Screening for Coronary Artery Disease
(CAD)
Diabetes Care 2018;41(S1).
![Page 8: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/8.jpg)
Stroke
No ADA guidelines for
screening for
cerebrovascular disease in
asymptomatic patients
![Page 9: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/9.jpg)
Peripheral Arterial Disease (PAD)
Cholesterol
(plaque)
embolization
Severe
ischemia in
setting of
infection
![Page 10: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/10.jpg)
Screening for Peripheral Arterial
Disease (PAD)
• PAD
– Routine foot examination (including pulses)
– Ankle brachial index (ABI)
• Symptomatic patients (claudication)
• Asymptomatic
– Not specifically addressed in 2018 ADA guidelines
![Page 11: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/11.jpg)
Why isn’t there greater emphasis on
screening for these macrovascular
complications?
![Page 12: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/12.jpg)
Diabetes Care 2018;41(S1).
Blood pressure target: < 140/90
Cholesterol treatment: Statins
A1c target: < 7-8%
![Page 13: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/13.jpg)
![Page 14: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/14.jpg)
2017
2018
Therapies added to metformin
should be based on presence or
absence of CVD
![Page 15: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/15.jpg)
See Table 8.1 for a helpful comparison of CV/renal
effects of available hyperglycemic agents
Diabetes Care 2018;41(S1).
![Page 16: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/16.jpg)
Which of the following antihyperglycemic therapies has
NOT been linked to a reduction in cardiovascular events
or mortality?
A. Liraglutide
B. Pioglitazone
C. Empagliflozin
D. Sitagliptin
![Page 17: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/17.jpg)
Diabetes Care 2018;41(S1).
Blood pressure target: < 140/90
Cholesterol treatment: Statins
A1c target: < 7-8%
(Happy to share
these slides with
you!)
![Page 18: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/18.jpg)
Diabetes Care 2018;41(S1).
Blood pressure target: < 140/90
Cholesterol treatment: Statins
A1c target: < 7-8%
![Page 19: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/19.jpg)
Diabetes Care 2018;41(S1).
Revised statin
guidelines for 2018
• Consolidated middle and older ages
• Less aggressive recommendations for younger patients
• Increased emphasis on LDL targets
![Page 20: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/20.jpg)
How about other interventions besides
blood glucose, blood pressure, and
cholesterol lowering?
![Page 21: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/21.jpg)
Which of the following interventions has the greatest
impact on survival in patients with diabetes?
A. Blood pressure control
B. Lipid lowering
C. Aspirin
D. Smoking cessation
![Page 22: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/22.jpg)
Smoking cessation
Meta-analysis: Smoking cessation has greater impact
on survival than several other interventions
![Page 23: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/23.jpg)
Aspirin
Primary prevention
Secondary prevention
Diabetes Care 2018;41(S1).
![Page 24: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/24.jpg)
(PREDIMED Study)
• ~7500 participants with high CV
risk but NO known CVD (~50%
with diabetes)
• Mediterranean diet vs low fat diet;
no caloric restriction
![Page 25: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/25.jpg)
• Cardiovascular events cut by 30%
• NNT: 61 patients
• No adverse effects
Trial stopped early at median
of 4.8 yrs based on interim
analysis
![Page 26: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/26.jpg)
What happens when we combine all of
these interventions?
![Page 27: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/27.jpg)
![Page 28: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/28.jpg)
• Subjects
– T2D (n=160)
– Microalbuminuria
– Mean age 55 yrs
– Randomized to
conventional vs
intensive therapy
• Goals of intervention
– A1c < 6.5%
– Chol < 175 mg/dL
– Trig < 150 mg/dL
– SBP < 130 mmHg
– DBP < 80 mmHg
– ACE/ARB
– ASA 81 mg/day
Multifactorial Intervention
![Page 29: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/29.jpg)
Cardiovascular death reduced by
57%
![Page 30: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/30.jpg)
How is greater recognition of the impact of
multifactorial intervention affecting
cardiovascular outcomes in patients with
diabetes?
Real world experience:
![Page 31: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/31.jpg)
Fewer
patients with
type 2
diabetes
dying of
CVD
N Engl J Med 2017;376:1407-18.
![Page 32: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/32.jpg)
Fewer
patients with
type 1
diabetes
dying of
CVD
N Engl J Med 2017;376:1407-18.
![Page 33: Prevention of MACROvascular Complications of Diabetes · 1. To recognize macrovascular complications as the leading cause of death in people with diabetes 2. To be familiar with risk](https://reader033.vdocuments.net/reader033/viewer/2022060218/5f06a2097e708231d418f661/html5/thumbnails/33.jpg)
Questions?